Company Description

Exicure, Inc. does not have significant operations.

Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets.

The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas.

Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

Exicure, Inc.

Country	United States
Founded	2011
Industry	Biotechnology
Sector	Healthcare
Employees	8
CEO	Jungsoo Kim

Contact Details

Address: 400 Seaport Court, Suite 102 Redwood City, California 94063 United States
Phone	847 673 1700
Website	exicuretx.com

Stock Details

Ticker Symbol	XCUR
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	1698530
CUSIP Number	30205M101
ISIN Number	US30205M3097
Employer ID	81-5333008
SIC Code	2834

Key Executives

Name	Position
Jungsoo Kim	Chief Executive Officer, President and Director
Gyuyeob Lee	Interim Chief Financial Officer and Secretary
Young Seung Ko	Chief Operating Officer
Joshua Miller	Chief Accounting Officer
Dr. Devki Sukhtankar Ph.D.	Head of Preclinical Research and Translational Medicine
Dr. Niña Caculitan Ph.D.	Head of Clinical

Latest SEC Filings

Date	Type	Title
May 15, 2026	NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
Apr 10, 2026	8-K	Current Report
Apr 2, 2026	8-K	Current Report
Mar 27, 2026	8-K	Current Report
Mar 25, 2026	10-K	Annual Report
Mar 25, 2026	8-K	Current Report
Feb 17, 2026	8-K	Current Report
Feb 10, 2026	8-K	Current Report
Jan 22, 2026	8-K	Current Report
Jan 21, 2026	SCHEDULE 13D/A	Filing

View All SEC Filings